Results 171 to 180 of about 1,518,868 (239)

De‐Escalation of Neoadjuvant Treatment for HER2‐Positive Breast Cancer

International Journal of Cancer, EarlyView.
ABSTRACT With improved prognosis in early HER2‐positive breast cancer, safely de‐escalating treatment is increasingly investigated to minimize overtreatment. This article focuses on neoadjuvant de‐escalation strategies for HER2‐positive breast cancer.
Yiyin Ma, Dedian Chen, Sheng Huang
wiley   +1 more source

Tolerability of Adjuvant Nivolumab in Esophageal or Gastroesophageal Junction Cancer: A Real‐World Study

International Journal of Cancer, EarlyView.
ABSTRACT Adjuvant nivolumab is approved for esophageal or gastroesophageal junction cancer after neoadjuvant chemoradiotherapy and resection. In the CheckMate‐577 trial, Grade 3–5 nivolumab‐related adverse events (AEs) occurred in 5% of patients, with early discontinuation due to toxicity in 9%. However, real‐world data on immunotherapy‐related adverse
Michelle Koops van ’t Jagt, Anniek Strijdhorst, Tamara Jessica Huizer, Esther Albertien Kleibeuker, Sarah Derks, Bianca Mostert, Hanneke van Laarhoven, Jacco Juri de Haan   +7 more
wiley   +1 more source

Diabetes Increases Immunotherapy‐Related Toxicity but Not Efficacy in Metastatic Non‐Small Cell Lung Cancer: A Multicenter Retrospective Study

International Journal of Cancer, EarlyView.
ABSTRACT This multicenter retrospective study evaluated the impact of type 2 diabetes mellitus (DM) on clinical outcomes and immune‐related adverse events (irAEs) in 450 patients with metastatic non‐small cell lung cancer (NSCLC) treated with second‐line nivolumab at 17 centers between 2016 and 2024. Among these patients, 118 (26.2%) had DM.
Emre Çakır, Didem Divriklioğlu, Deniz Can Güven, Gamze Serin Özel, Oğuzhan Yıldız, Gamze Emin, Merve Keskinkılıç, Yeşim Ağyol, Onur Yazdan Balçık, Nagihan Kolkıran, Hale Gülçin Yıldırım Doğan, Pervin Can Şancı, Özge Yalıcı, Teoman Şakalar, Yurdagül Danacı, Yakup Düzköprü, Canan Yıldız, Mesut Yılmaz, İlhan Hacıbekiroğlu, Bülent Erdoğan, Saadettin Kılıçkap, Gamze Gököz Doğu, Melek Karakurt Eryılmaz, Atila Yıldırım, İlhan Öztop, İbrahim Vedat Bayoğlu, Şahnura Uzuntaş, Atike Pınar Erdoğan, Emir Çelik, Devrim Çabuk, Erdoğan Selçuk Şeber, Zehra Sadak Öcal, Hacer Demir   +32 more
wiley   +1 more source

Incidence and Predictors of Immune‐Related Hypothyroidism Under Pembrolizumab Across Gynecologic Malignancies and Melanoma: A Real‐World Cohort Study

International Journal of Cancer, EarlyView.
ABSTRACT Immune checkpoint inhibitors (ICIs) frequently cause thyroid immune‐related adverse events (irAEs). Permanent hypothyroidism, the clinically most relevant phenotype, requires lifelong hormone replacement. We investigated its incidence, course, risk factors, and prognostic relevance under pembrolizumab.
Freya Koffka, Johann Kornowski, Elena Laakmann, Barbara Schmalfeldt, Tim Zell, Glenn Geidel, Christoffer Gebhardt, Pia Roser, Volkmar Müller, Julian Kött   +9 more
wiley   +1 more source

Perioperative Avelumab and Chemotherapy for Gastroesophageal Adenocarcinoma: Long‐Term Survival Outcomes

International Journal of Cancer, EarlyView.
ABSTRACT Long‐term survival data for patients with locally advanced gastro‐esophageal adenocarcinoma (GEA) treated with neoadjuvant chemoimmunotherapy are lacking. We describe the long‐term disease‐free survival (DFS) and overall survival (OS) outcomes of such patients treated with a novel neoadjuvant chemoimmunotherapy regimen, aDCF (avelumab with ...
Thierry Alcindor, James Tankel, Pierre‐Olivier Fiset, Mehrnoush Dehghani, Nicholas Bertos, Carmen Mueller, Jonathan Cools‐Lartigue, Sophie Camilleri‐Broet, Lorenzo Ferri   +8 more
wiley   +1 more source

Engineering Bacteria for Medicine: Delivery, Diagnosis, and Therapy

iMetaMed, EarlyView.
ABSTRACT With rapid advances in synthetic biology and genetic engineering, genetically engineered bacteria (GEB) have emerged as a promising platform for biological therapy, addressing key limitations of conventional drug delivery systems and demonstrating significant clinical potential.
Shiyu Xia, Guiling Fu, Xiaoyue Ding, Wen Yang, Ruijie Bai, Yawei Cai, Jing xuan Zhang, Yanxia Wei, Conghui Han, Yi‐Zhou Gao, Ying Li, Zuobin Zhu   +11 more
wiley   +1 more source

Human biomarker navigator

iMeta, EarlyView.
The Human Biomarker Navigator integrates the disease continuum, biomarker dynamics, cross‐organ biomarker networks, biomarker classification, and technology‐driven paradigms. It maps how biomarkers link multi‐system physiology and pathology across the nervous, respiratory, endocrine, circulatory, immune, digestive, urinary, reproductive, and ...
Meng‐Yao Li, Qian Zhang, Zijie Wang, Zeping Gui, Jing Liu, Jingda Li, Maojun Jiang, Zukang Chang, Qingqing Han, Bendong Yang, Tariq Saeed, Jun Li, Jinghan Jia, Chenghu Song, Tong Shao, Tianhuan Peng, Xueying Zhang, Pingping Guo, Jun Luo, Gangao Yang, Yuan Wan, Gokhan Zengin, Quan Yuan, Lingru Li, Xiaohui Fan, Yang Luo, Lvyun Zhu, Yanfei Zheng, Wenjun Mao, Wenlong Sun   +29 more
wiley   +1 more source

Multi‐omics–driven precision medicine

iMeta, EarlyView.
Multi‐omics‐driven precision medicine (MODPM) provides a multiscale, continuously learnable framework that integrates genomics, epigenomics, transcriptomics, proteomics, metabolomics, microbiome profiles, and clinical data. Powered by artificial intelligence and foundation models, MODPM enables cross‐modal representation learning, contextual modeling ...
Huibo Li, Zhe Zhao, Yifan Zhang, Yao Ma, Gaofei Hu, Min Zeng, Zhanqun Yang, Zixuan Zhao, Xin Zhou, Wei Hu, Yuxuan Sun, Meng Su, Jun Li, Matthew Whiteman, Wei Fu, Chao Zhong, Lemin Zheng, Long Chen, Hairong Lv, Rongsheng Zhao, Yi Zhun Zhu   +20 more
wiley   +1 more source

Ovarian Cancer: Epidemiology, Disease Mechanisms, New Diagnosis and Treatment Strategies, and Research Directions

iNew Medicine, EarlyView.
ABSTRACT Ovarian cancer (OC) continues to be the deadliest gynecological malignancy and a significant cause of cancer‐related mortality among women worldwide. Standard treatment strategies typically entail platinum‐based chemotherapy in conjunction with cytoreductive surgery.
Zunera Khalid, Weirong Fan, Farah Nazir, Yixiang Xing, Tengchuan Jin   +4 more
wiley   +1 more source

ATP Citrate Lyase in Metabolic Disease: Mechanistic Insights and Clinical Potential

iNew Medicine, EarlyView.
ATP citrate lyase (ACLY) is a central metabolic hub that diverts mitochondrial citrate to fuel de novo lipogenesis, cholesterol biosynthesis, and protein acetylation. Given its robust correlation with pathological changes in multiple human diseases, ACLY inhibitors featuring distinct pharmacological strengths have been developed for therapeutic ...
Wenbiao Wang, Xinyan Li, Honglu Shi, Gaolei Song, Zhifu Xie, Jingya Li   +5 more
wiley   +1 more source